MPM BioImpact LLC
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.30B2026 Q3+ $48.6M options (notional, not included)
Positions37
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.48.1%
What Changed This Quarter?
Top Holdings
CGEM
Cullinan Therapeutics
11.1%
AKTS
Aktis Oncology
7.0%
TVTX
Travere Therapeutics
4.8%
EWTX
Edgewise Therapeutics
4.7%
DYN
Dyne Therapeutics
3.8%
CORT
Corcept Therapeutics
3.6%
CORTPUT
Corcept Therapeutics
3.6%
RLAY
Relay Therapeutics
3.2%
New / Increased
10 new · 8 increased
CORTPUTNEW
Corcept Therapeutics
3.6%
IOVANEW
Iovance Biotherapeutics
3.1%
IMCRNEW
Immunocore
2.7%
VIRNEW
Vir Biotechnology
2.3%
VSTMNEW
Verastem
2.3%
ACRS
Aclaris Therapeutics
2.0%
+396.7%
DYN
Dyne Therapeutics
3.8%
+66.9%
TSHA
Taysha Gene Therapies
2.6%
+61.4%
Reduced / Exited
18 reduced · 10 sold out
CORT
Corcept Therapeutics
3.6%
-45.3%
DBVT
DBV Technologies S
2.7%
-17.0%
TVTX
Travere Therapeutics
4.8%
-3.1%
EWTX
Edgewise Therapeutics
4.7%
-2.8%
TRVI
Trevi Therapeutics
3.2%
-3.1%
RVMDEXIT
Revolution Medicines
5.6%
ALMSEXIT
Alumis
3.5%
RAREEXIT
Ultragenyx Pharmaceuticals
2.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.